Berenberg Bank Analysts Give Merck KGaA (MRK) a €111.00 Price Target
Berenberg Bank set a €111.00 ($137.04) price objective on Merck KGaA (FRA:MRK) in a research report sent to investors on Tuesday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other analysts also recently weighed in on the stock. JPMorgan Chase & Co. set a €95.00 ($117.28) target price on shares of Merck KGaA and gave the company a neutral rating in a research report on Monday, February 26th. Warburg Research set a €115.00 ($141.98) target price on shares of Merck KGaA and gave the company a buy rating in a research report on Friday, February 16th. UBS Group set a €120.00 ($148.15) target price on shares of Merck KGaA and gave the company a buy rating in a research report on Friday, February 16th. DZ Bank reissued a buy rating on shares of Merck KGaA in a research report on Monday, February 12th. Finally, Kepler Capital Markets set a €115.00 ($141.98) target price on shares of Merck KGaA and gave the company a buy rating in a research report on Wednesday, January 17th. Eleven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of €106.57 ($131.57).
Shares of Merck KGaA (MRK) opened at €78.46 ($96.86) on Tuesday. The firm has a market cap of $10,250.00 and a P/E ratio of 18.37. Merck KGaA has a 52-week low of €78.34 ($96.72) and a 52-week high of €115.00 ($141.98).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.